<< Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum | Greg Peet elected as Chairman of Vigil Health Solutions >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Русский | Svenska | Polski

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

Published on August 24, 2009 at 1:06 AM · No Comments

iCo Therapeutics Inc. (TSX-V: ICO) today reported financial results for the quarter ended June 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

Summary Q2 2009 Results

We incurred a net and comprehensive loss of $556,886 for the three months ended June 30, 2009 compared to a net and comprehensive loss of $671,290 for the three months ended June 30 2008, representing a decrease of approximately $114,404. The decrease in our net and comprehensive loss was principally caused by a decrease in both research and development expenses and general and administrative expenses.

Interest income for the three months ended June 30, 2009 was $621, compared to $4,646 for the three month period ending June 30, 2008, resulting in a decrease of $4,025. The lower interest income earned in the three month period ending June 30, 2009, as compared to the same period in 2008 was a result of smaller cash and short term investments balances held in our treasury in 2009 combined with lower interest rates.

Research and development expenses were $280,116 for the three months ended June 30, 2009 compared to $365,276 for the three months ended June 30, 2008, representing a decrease of $85,160, primarily due to a reduction in personnel salaries and consultants' fees.

For the three months ended June 30, 2009 general and administrative expenses were $201,940 compared to $243,742 for the three months ending June 30, 2008, representing a decrease of $41,802. This decrease in the three months ending June 30, 2009 compared to the three months ending June 30, 2008 were attributable to decreases in personnel salaries and professional fees.

Amortization for the three months ended June 30, 2009 was $28,825 compared to amortization of $28,792 for the three months ended June 30, 2008, an increase of $33. Amortization for the six months ended June 30, 209 was $57,764 compared to amortization of $57,957 for the six months ended June 30, 2008, an increase of $193.

Foreign exchange loss for the three months ended June 30, 2009 was $8,918 compared to foreign exchange gain of $7,673 for the same period in 2008, representing a decrease of $16,591. Foreign exchange loss for the six months ended June 30, 2009 was $27,070 compared to foreign exchange gain of $8,632 for the same period in 2008, representing a decrease of $35,702.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading